Joel Schlessinger is a Dermatology physician affiliated with University of Nebraska at Omaha. OpenAlex indexes 94 publications with 2,160 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2802 Oak View Drive
Omaha, NE 681445604
Telephone
402-334-7546Registry record last updated 3 Apr 2012.
Clinical trials
- Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
Sponsor: Revance Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Nielsen BioSciences, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- ABBVIE INC.Program year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
57.7%First-generation cephalosporins24.3%Cephalexin100%Part D≥238 patientsAzole Antifungal12.5%Ketoconazole55%Fluconazole45%Part D≥65 patients+ 7 more classes in this area
Dermatology
20.3%Allylamine Antifungal10.3%Terbinafine Hcl100%Part D≥55 patientsCorticosteroid6.2%Triamcinolone Acetonide100%Part D≥73 patients+ 2 more classes in this area
Respiratory
9.2%RNA Synthetase Inhibitor Antibacterial9.2%Mupirocin100%Part D≥112 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies
Journal of the American Academy of Dermatology
2025 - Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials
Plastic & Reconstructive Surgery Global Open
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Rennard, MD
University of Nebraska at Omaha
Philip Bierman, MD
University of Nebraska at Omaha
Rudy Lackner, MD
University of Nebraska at Omaha
Iraklis Pipinos, MD
University of Nebraska at Omaha
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”